This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Janssen, W. M. Articles by de Jong, P. E. Search for Related Content PubMed PubMed Citation Articles by Janssen, W. M. Articles by de Jong, P. E.

Hypertension, Vol 13, 640-646, Copyright © 1989 by American Heart Association

ARTICLES

Antihypertensive effect of a 5-day infusion of atrial natriuretic factor in humans

WM Janssen, D de Zeeuw, GK van der Hem and PE de Jong
Department of Medicine, State University Hospital Groningen, The Netherlands.

Atrial natriuretic factor was infused in a low dose (0.2 microgram/min) during 5 days in six patients with essential hypertension. Atrial natriuretic factor infusion caused plasma levels of atrial natriuretic factor to increase from 49 +/- 10 to 106 +/- 19 pg/ml. Within 4 hours after the start of the atrial natriuretic factor infusion, urinary sodium excretion increased in all subjects. Sodium balance was regained after 24 hours with a net loss of 72.3 +/- 14.6 mmol. However, systolic as well as diastolic blood pressure started to decrease gradually in all subjects only after 12 hours of atrial natriuretic factor infusion, reaching a stable level after 36 hours with a decrease of 11.5 +/- 1.5% and 10.3 +/- 0.8%, respectively. Heart rate increased in parallel by 12.6 +/- 3.1%. Hematocrit rose 7.1 +/- 2.3%. After cessation of atrial natriuretic factor infusion, plasma atrial natriuretic factor levels, sodium balance, and hematocrit returned to baseline within 24 hours, whereas blood pressure slowly returned toward baseline values over 3 days. These data show that chronic atrial natriuretic factor infusion in patients with essential hypertension causes a negative sodium balance and a rise in hematocrit, followed by a smooth decrease in blood pressure with a rise in heart rate until a new equilibrium is reached after approximately 2 days. Thus, atrial natriuretic factor in low doses appears intimately involved in the regulation of sodium balance and blood pressure in humans. Moreover, these data suggest that atrial natriuretic factor-like substances will eventually become useful antihypertensive drugs.

This article has been cited by other articles:

				M. P. van den Berg, I. C. van Gelder, and D. J. van Veldhuisen Depletion of atrial natriuretic peptide during longstanding atrial fibrillation Europace, January 1, 2004; 6(5): 433 - 437. [Abstract] [Full Text] [PDF]

				F. Regamey, M. Maillard, J. Nussberger, H. R. Brunner, and M. Burnier Renal Hemodynamic and Natriuretic Effects of Concomitant Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Men Hypertension, September 1, 2002; 40(3): 266 - 272. [Abstract] [Full Text] [PDF]

				V. M. Campese, K. C. Lasseter, C. M. Ferrario, W. B. Smith, M. C. Ruddy, C. E. Grim, R. D. Smith, R. Vargas, M. F. Habashy, O. Vesterqvist, et al. Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients Hypertension, December 1, 2001; 38(6): 1342 - 1348. [Abstract] [Full Text] [PDF]

				G. A. Sagnella Atrial natriuretic peptide mimetics and vasopeptidase inhibitors Cardiovasc Res, August 15, 2001; 51(3): 416 - 428. [Abstract] [Full Text] [PDF]

				F. Boomsma and A. H. van den Meiracker Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use Cardiovasc Res, August 15, 2001; 51(3): 442 - 449. [Full Text] [PDF]

				F. Ruschitzka, R. Corti, T. Quaschning, M. Hermann, and T. F. Luscher Vasopeptidase inhibitors--concepts and evidence Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1532 - 1535. [Full Text] [PDF]

				R. E. Chatelain, R. D. Ghai, A. J. Trapani, L. M. Odorico, B. N. Dardik, S. De Lombaert, R. W. Lappe, and C. A. Fink Antihypertensive and Natriuretic Effects of CGS 30440, a Dual Inhibitor of Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11 J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 974 - 982. [Abstract] [Full Text]

				V. M. Campese, M. Tawadrous, R. Bigazzi, S. Bianchi, A. S. Mann, S. Oparil, and L. Raij Salt Intake and Plasma Atrial Natriuretic Peptide and Nitric Oxide in Hypertension Hypertension, September 1, 1996; 28(3): 335 - 340. [Abstract] [Full Text]

				G. B. Pidgeon, A. M. Richards, M. G. Nicholls, E. A. Espiner, T. G. Yandle, and C. Frampton Differing Metabolism and Bioactivity of Atrial and Brain Natriuretic Peptides in Essential Hypertension Hypertension, April 1, 1996; 27(4): 906 - 913. [Abstract] [Full Text]

				K.-F. Lin, J. Chao, and L. Chao Human Atrial Natriuretic Peptide Gene Delivery Reduces Blood Pressure in Hypertensive Rats Hypertension, December 1, 1995; 26(6): 847 - 853. [Abstract] [Full Text]